21st Annual Pediatric Endocrinology and Diabetes Symposium

Monday, November 14, 2022, 8:30 AM - 1:00 PM, Online


IN LIGHT OF THE DIABETES EPIDEMIC AND THE HIGH FREQUENCY OF PEDIATRIC CHRONIC DISEASES AND GROWTH DISORDERS, THE MOUNT SINAI DIVISION OF PEDIATRIC ENDOCRINOLOGY AND DIABETES SEEKS TO EMPOWER A BROAD ARRAY OF CLINICIANS TO PROVIDE THE HIGHEST LEVEL OF CARE TO PEOPLE WITH DIABETES AND DISORDERS OF GROWTH. PARTICIPANTS WILL LEARN ABOUT PATHOPHYSIOLOGY, TREATMENT GOALS AND TREATMENT METHODS FOR DIABETES, ENDOCRINE DISORDERS AND GROWTH DISORDERS AND WILL EMERGE MORE CONFIDENT DEALING WITH DIABETES AND ENDOCRINE CHALLENGES.

1. Review recent findings on neonatal thyroid disorders
2. Identify the underlying etiologies of growth disorders and understand new concepts in the diagnosis and management of short stature
3. Review the key findings from the US Type 1 Diabetes COVID19 Surveillance Project 21st Annual Symposium Pediatric Endocrinology and Diabetes

Practicing Physician - $30.00

MSHS Allied Health Professional - $15.00

MSHS Resident/Fellow/Medical Student - Complimentary*

**PLEASE EMAIL A COPY OF YOUR HOSPITAL ID TO [email protected] TO RECEIVE A COMPLIMENTARY REGISTRATION CODE**

Cancellation Policy

All cancellation requests must be emailed to the CME office at [email protected] by October 21, 2022. No refunds will be issued for for this course.

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (3.00 hours), Non-Physician Attendance (3.00 hours)

You are not logged in.

Please click the button below to login or create a new account before continuing.

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Mitigation of Relevant Financial Relationships

It is the policy of Icahn School of Medicine at Mount Sinai (ISMMS) to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-accredited educational activities. All faculty participating in the planning or implementation of an activity accredited by ISMMS are expected to disclose all of their financial relationships with ineligible companies existing within the prior 24 months. Relevant financial relationships will be mitigated and disclosed to learners before the activity takes place. Presenters must also make a meaningful disclosure to the audience of their discussion of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Monday, November 14, 2022

In Partnership with: